Iron Deficiency Anemia Treatments
Recommendations for the management of iron deficiency anemia including oral and intravenous iron therapies.
Hematologic Disorders
Study Investigating Rivipansel in Patients With Sickle Cell Disease Misses End Points
The primary end point was time to readiness for discharge, defined as the difference between the readiness-for-discharge date and time and the start date and time of the first infusion of study drug.
Nipocalimab Gets Fast-Tracked for Hemolytic Disease of the Fetus and Newborn
The Food and Drug Administration (FDA) has granted Fast Track designation to nipocalimab (M281) for the prevention of hemolytic disease of the fetus and newborn (HDFN).
New Oral Therapy Approved for Iron Deficiency in Adults
The FDA has approved Accrufer (ferric maltol; Shield Therapeutics) for the treatment of iron deficiency in adults.
Crizanlizumab Granted Priority Review for Sickle Cell Pain Crises Prevention
Priority Review shortens the FDA review time from 10 months to 6 months
Thromboembolic Disorder Assessment: DVT/PE
Risk factors, prevention strategies, signs & symptoms, and general treatment options for deep vein thrombosis (DVT) and pulmonary embolism (PE).
Chemotherapy-Free Combo Therapy Approved for Previously Untreated CLL
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Tibsovo Approved to Treat Newly Diagnosed AML With IDH1 Mutation
The FDA has expanded the indication for Tibsovo to include treatment of newly diagnosed acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Anticoagulant Dosing Conversions
Recommended dosing conversions for anticoagulants such as warfarin, heparin, and dabigatran.
Bleeding Disorder Treatments: Hemophilia A
Treatment options for Hemophilia A including factors and other biologics.
